Our client is currently developing a new functionalized silica nanoparticle as a drug delivery vector for nucleic acid payloads.

  • These nanoparticles are hollow silica spheres covered in thin silica structures functionalized with polyethyleneimine (PEI) to enhance binding of macromolecules.
  • The nanoparticles can be manufactured in a controlled manner to range from 80 – 500 nm in size. Standard nanoparticles are 180nm diameter.
  • The unique surface structure of the nanoparticles provides a large surface area that traps and protects the looped structure of oligonucleotides, such as siRNA, DNA, mRNA, and others.

This nanoparticle system has been designed to deliver nucleic acids directly into cells and to overcome many of the weaknesses of lipid and viral delivery systems.


  • Significant opportunities exist for a novel delivery system to deliver many innovative new vaccine products and nucleic acid therapeutics.
  • Applications include: Cancer Therapeutics, Cancer Vaccines, and Prophylactic vaccines for hard to treat diseases such as influenza, zika, ebola, and coronaviruses.
  • Additional uses for this platform include delivery of peptides, production of viral vectors, small molecule use, and more.
  • Transfection using pDNA/mRNA loaded nanoparticles has been confirmed in a range of human and animal cell lines.
  • Evidence of payload protection from complete degradation following nuclease treatment has been obtained.
  • Toxicology, Pharmacology, and Chemistry, Manufacturing, and Controls (CMC) work has all been initiated with positive findings.

Partnering Opportunities

  •  Our client is seeking co-development and licensing partners for applications in oncology and vaccines.
  • They wish to engage with companies that have pDNA, mRNA, or siRNA assets that are seeking an improved delivery platform.
  • They will also consider collaboration for continued development of their nanoparticle platform up to pre-agreed milestones.